Form D · Biotechnology
CuraSen Therapeutics, Inc.
San Carlos, CA · CIK 0001765883
Offering snapshot reported Sep 18, 2024 · SEC filing
- Reported sold
- $5.79M Offering amount: $45.7M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 26, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 18, 2024 | Initial | $5,785,019 | No comparison | 7 | SEC filing |
| Oct 12, 2023 | Amendment | $17,599,997 | $2,600,000vs Nov 10, 2022 | 11 | SEC filing |
| Nov 10, 2022 | Initial | $14,999,997 | No comparison | 10 | SEC filing |
| Nov 5, 2021 | Initial | $18,000,000 | No comparison | 10 | SEC filing |
| Jan 25, 2019 | Initial | $27,249,994 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-524399
Source: Form D, filed Sep 18, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patrick Enright | Director |
| Anthony P. Ford | Director, Executive |
| Kathleen Sereda Glaub | Director |
| Ron Hunt | Director |
| Benjamin Potter | Executive |
| Liam Ratcliffe | Director |
| Henry Skinner | Director |
| Simon Tate | Director |
| Simon Tate, Ph.D. | Director |
| Loretta Tse, Ph.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
733 Industrial Road
San Carlos, CA, 94070
San Carlos, CA, 94070